Literature DB >> 8030401

Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results.

G B Frisoni1, G Pizzolato, A Bianchetti, F Chierichetti, G Ferlin, L Battistin, M Trabucchi.   

Abstract

Dementia of frontal type (DFT) is a fairly common degenerative disease distinct from Alzheimer's disease (AD), whose reportedly distinctive instrumental feature is frontal lobe hypoperfusion on SPECT. We evaluated the cortical dopaminergic system in 6 AD, 5 DFT, and 6 control subjects with SPECT and both [99Tc]-HM-PAO, a perfusion tracer, and [123I]-IBZM, a D2 postsynaptic ligand. Both in AD and DFT patients, [99Tc]-HM-PAO SPECT showed a relative frontal hypoperfusion. On the contrary, [123I]-IBZM SPECT showed significantly reduced ligand uptake in superior frontal regions of DFT (0.89 +/- 0.08 relative to control subjects) as compared to AD patients (0.97 +/- 0.02; difference of means: 0.08, 95% Confidence Interval 0.004 to 0.156; p = 0.041). Results suggest more marked involvement of the frontal cortical dopaminergic system in DFT than in AD patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8030401     DOI: 10.1111/j.1600-0404.1994.tb01661.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  12 in total

1.  Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration.

Authors:  Tiffany W Chow; Mario F Mendez
Journal:  Am J Alzheimers Dis Other Demen       Date:  2002 Sep-Oct       Impact factor: 2.035

Review 2.  [Frontotemporal dementias].

Authors:  K Witt; G Deuschl; T Bartsch
Journal:  Nervenarzt       Date:  2013-01       Impact factor: 1.214

Review 3.  Reward processing in neurodegenerative disease.

Authors:  David C Perry; Joel H Kramer
Journal:  Neurocase       Date:  2014-01-13       Impact factor: 0.881

Review 4.  Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.

Authors:  Gregory A Jicha
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

5.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

6.  FTLD Treatment: Current Practice and Future Possibilities.

Authors:  Peter A Ljubenkov; Adam L Boxer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia.

Authors:  Edward D Huey; Karen T Putnam; Jordan Grafman
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

8.  SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele.

Authors:  M Lehtovirta; H Soininen; M P Laakso; K Partanen; S Helisalmi; A Mannermaa; M Ryynänen; J Kuikka; P Hartikainen; P J Riekkinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

9.  A new approach for improving diagnostic accuracy in Alzheimer's disease and frontal lobe dementia utilising the intrinsic properties of the SPET dataset.

Authors:  Marco Pagani; Vassili A Kovalev; Roger Lundqvist; Hans Jacobsson; Stig A Larsson; Lennart Thurfjell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-29       Impact factor: 9.236

Review 10.  Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia.

Authors:  Christine Le; Elizabeth Finger
Journal:  CNS Drugs       Date:  2021-08-24       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.